Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12158461 | 0.85 | NPC1 (0.37) | SCN10ANPY5RNLNSCN5A | |
| SCHEMBL16355457 | 0.83 | SCN10A (0.43) | CYP1A1CYP1A2CYP1B1SCN10ANLN | |
| SCHEMBL16355447 | 0.81 | CDK5 (0.41) | CYP1A2 | |
| SCHEMBL16355449 | 0.80 | PTGES (0.43) | HDAC1 | |
| SCHEMBL16355444 | 0.80 | PTGES (0.43) | HDAC1 | |
| SCHEMBL16355442 | 0.80 | SCN10A (0.36) | SCN10ANLNSCN5A | |
| SCHEMBL14300085 | 0.76 | NPC1 (0.34) | NLNHDAC1 | |
| SCHEMBL14274103 | 0.76 | SCN5A (0.34) | SCN10ANLNSCN5A | |
| SCHEMBL12107457 | 0.76 | NLN (0.41) | NLNHDAC1 | |
| SCHEMBL16355460 | 0.70 | NLN (0.30) | NLN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378416-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378416-A1 | SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ZC3HAV1L, HBS1L, HAVCR2 | CYP1A1 713/4885CYP1A2 585/4885CYP1B1 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.